COLL - NASDAQ
Collegium Pharmaceutical, Inc.
$31.06
+1.9%Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
At a Glance
Live SnapshotCollegium Pharmaceutical, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
Collegium Pharmaceutical, Inc. Cash Flow Statement
COLL • NASDAQ
| Collegium Pharmaceutical, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||
62.9M | 69.2M | 48.2M | -25M | 71.5M | 26.8M | -22.7M | -39.1M | -74.9M | -94.2M | -27.3M | -17.9M | -16.2M | |
220.8M | 169.2M | 149.3M | 138.9M | 68.9M | 61.6M | 15.5M | 110.9M | 594K | 655K | 171K | 187K | 169K | |
-25.7M | -26.8M | -2.2M | -8.4M | -78M | 0.0 | 0.0 | 0.0 | 1.8M | 0.0 | 0.0 | 0.0 | 79K | |
41.9M | 32.4M | 27.1M | 22.9M | 24.3M | 21.9M | 16.5M | 13.8M | 7.9M | 5.8M | 2.2M | 22K | 62K | |
25.6M | 16M | 30.6M | 8.5M | 3.4M | 9M | 313K | 19.3M | -34K | -34K | -28K | -20K | -9K | |
(0.0) | (52.1M) | (24.2M) | (10.4M) | (3M) | (483K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
3.8M | -55M | 21.7M | -12.7M | 13.5M | -25.3M | 18.2M | 64.6M | -2.5M | 12.7M | 3.3M | -219K | -634K | |
329.3M | 205M | 274.7M | 124.2M | 103.6M | 93.9M | 27.8M | 169.4M | -67M | -75.1M | -21.6M | -17.9M | -16.5M | |
INVESTING ACTIVITIES | |||||||||||||
-1.7M | -1.7M | -461K | -1.6M | -1.9M | -5.5M | -6.4M | -24.4M | -990K | -3M | -362K | -8K | -206K | |
(0.0) | -267.5M | (0.0) | -572.1M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-127M | -111.2M | -92.4M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
65.2M | 92.6M | 22M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -368.2M | 0.0 | -18.9M | 0.0 | -2.5M | 0.0 | 0.0 | 0.0 | |
-63.5M | -287.8M | -70.8M | -573.7M | -1.9M | -373.8M | -6.4M | -24.4M | -990K | -3M | -362K | -8K | -206K | |
FINANCING ACTIVITIES | |||||||||||||
-19.5M | -60M | -75M | -14.1M | -47.9M | 0.0 | 0.0 | -30K | 34.3M | 137.3M | 72M | 0.0 | 0.0 | |
-70.4M | 7.5M | -65.9M | 442.7M | -50M | 281.4M | 0.0 | 10M | -2.7M | -2.7M | -1.3M | 12M | 395K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -24.6M | -24.6M | (0.0) | (0.0) | |
-25.1M | -60M | -75M | -14.1M | -47.9M | (0.0) | -822K | -560K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-20.4M | -8.1M | 740K | 8.1M | 8.6M | 5.1M | 2M | -127.2M | 1.8M | 885K | 25.1M | 72K | 1K | |
-110.2M | -60.6M | -140.2M | 436.7M | -89.3M | 286.5M | 2M | -117.2M | 33.5M | 135.6M | 116M | 12M | 12.4M | |
CASH FLOW SUMMARY | |||||||||||||
155.5M | -143.4M | 63.8M | -12.7M | 12.3M | 6.6M | 23.4M | 27.8M | -34.5M | 57.5M | 94.1M | -5.9M | -4.4M | |
96.6M | 240M | 176.2M | 189M | 176.7M | 170M | 146.6M | 118.8M | 153.2M | 95.7M | 1.6M | 7.6M | 11.9M | |
252.2M | 96.6M | 240M | 176.2M | 189M | 176.7M | 170M | 146.6M | 118.7M | 153.2M | 95.7M | 1.6M | 7.6M | |
327.6M | 203.3M | 274.3M | 122.6M | 101.6M | -279.8M | 21.3M | 145M | -68M | -78M | -21.9M | -18M | -16.7M |
SEC Filings
COLL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 15, 2026 | May 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 07, 2026 | May 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 07, 2026 | April 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 |
Related Guides
Continue your COLL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.